Search - tctmd.com

Displaying 381 - 400 of 647

Sort: Relevancy | Date

Presentation TCT 2016

Why are These Trials Recruiting Slowly and How Can We Improve Recruitment Rates?

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Martin B. Leon

October 30, 2016

Presentation TCT 2016

Debate - Should Patients With Advanced Renal Disease Undergo PCI via Radial Access? Of Course! Renal Patients Are at the Highest Risk!

Presenter: Ian C. Gilchrist, James Nolan, Binita Shah

October 30, 2016

Presentation TCT 2016

Debate - Should Patients With Advanced Renal Disease Undergo PCI via Radial Access? No Way, Preserve Future Dialysis Access at All Costs!

Presenter: Ian C. Gilchrist, James Nolan, Michael S. Lee

October 30, 2016

Presentation TCT 2016

Assessment and Critical Appraisal of Ongoing RDN Studies: Will the Results Accurately Reflect RDN Effectiveness?

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Justin E. Davies

October 30, 2016

Presentation TCT 2016

Alcohol Chemical Neurolysis (Ablative Solutions): Peregrine Results and the Sham-controlled TARGET BP I Trial

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, David E. Kandzari

October 30, 2016

Presentation TCT 2016

Treatment of Renal Artery Fibromuscalar Dysplasia: Indications, Techniques, and Outcomes

Presenter: Gary M. Ansel, Michael R. Jaff, Mehdi H. Shishehbor

October 30, 2016

Presentation TCT 2016

Device Overview and Ongoing Study Design: Kona WAVE IV Trial

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Roland E Schmieder

October 30, 2016

Presentation TCT 2016

Renal Artery Fibromuscular Dysplasia: Natural History and Treatment

Presenter: Gary M. Ansel, Michael R. Jaff

October 30, 2016

Presentation TCT 2016

Device Overview and Ongoing Study Design: Recor RADIANCE HTN Study

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Laura Mauri

October 30, 2016

Presentation TCT 2016

Atheroscleotic Renal Artery Intervention: What Are the Remaining Indications?

Presenter: Gary M. Ansel, Michael R. Jaff, Sahil A. Parikh

October 30, 2016

Presentation TCT 2016

Device Overview and Ongoing Study Design: St. Jude's EnligHTN Program

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, William B. White

October 30, 2016

Presentation TCT 2016

Device Overview and Ongoing Study Design: Medtronic GLOBAL SYMPLICITY SPYRAL HTN Trial Program

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, David E. Kandzari

October 30, 2016

Presentation TCT 2016

Device Overview and Ongoing Study Design: Boston Scientific REINFORCE

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Ajay J. Kirtane

October 30, 2016

Presentation TCT 2016

Overcoming Clinical Design Issues: What to Look for (and Demand) in Ongoing and Future Hypertension Device Trials

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Bryan Williams

October 30, 2016

Presentation TCT 2016

LIVE-IN-A-BOX CASE DEMONSTRATION: Aortoiliac Intervention

Presenter: D. Christopher Metzger, Constantino S. Pena

October 30, 2016

Presentation TCT 2016

Overcoming RDN Catheter Design Limitations: Issues and Spectrum of Devices

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Horst Sievert

October 30, 2016

Presentation TCT 2016

Renal Denervation for Hypertension: New Insights and A Progress Report From Last Year

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Felix Mahfoud

October 30, 2016

Presentation TCT 2016

Management of Complications From Aortoiliac Intervention

Presenter: D. Christopher Metzger, Constantino S. Pena

October 30, 2016

Presentation TCT 2016

Hypertension Treatment Targets Beyond the Kidneys

Presenter: Felix Mahfoud, Michael A. Weber, Atul Pathak

October 30, 2016

Presentation TCT 2016

Optimal Stent Selection for Aortoiliac Intervention: Understanding the Differences

Presenter: D. Christopher Metzger, Constantino S. Pena, Ehrin J. Armstrong

October 30, 2016

Advertisement

Why are These Trials Recruiting Slowly and How Can We Improve Recruitment Rates?

Debate - Should Patients With Advanced Renal Disease Undergo PCI via Radial Access? Of Course! Renal Patients Are at the Highest Risk!

Debate - Should Patients With Advanced Renal Disease Undergo PCI via Radial Access? No Way, Preserve Future Dialysis Access at All Costs!

Assessment and Critical Appraisal of Ongoing RDN Studies: Will the Results Accurately Reflect RDN Effectiveness?

Alcohol Chemical Neurolysis (Ablative Solutions): Peregrine Results and the Sham-controlled TARGET BP I Trial

Treatment of Renal Artery Fibromuscalar Dysplasia: Indications, Techniques, and Outcomes

Device Overview and Ongoing Study Design: Kona WAVE IV Trial

Renal Artery Fibromuscular Dysplasia: Natural History and Treatment

Device Overview and Ongoing Study Design: Recor RADIANCE HTN Study

Atheroscleotic Renal Artery Intervention: What Are the Remaining Indications?

Device Overview and Ongoing Study Design: St. Jude's EnligHTN Program

Device Overview and Ongoing Study Design: Medtronic GLOBAL SYMPLICITY SPYRAL HTN Trial Program

Device Overview and Ongoing Study Design: Boston Scientific REINFORCE

Overcoming Clinical Design Issues: What to Look for (and Demand) in Ongoing and Future Hypertension Device Trials

LIVE-IN-A-BOX CASE DEMONSTRATION: Aortoiliac Intervention

Overcoming RDN Catheter Design Limitations: Issues and Spectrum of Devices

Renal Denervation for Hypertension: New Insights and A Progress Report From Last Year

Management of Complications From Aortoiliac Intervention

Hypertension Treatment Targets Beyond the Kidneys

Optimal Stent Selection for Aortoiliac Intervention: Understanding the Differences

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content